• emanuele.bruni@unicamillus.org

Emanuele Bruni

Applied Biology - Bio/13

Biography

He obtained a Bachelor’s Degree in Cellular and Molecular Biology, a Specialist Degree in Biology and Human Evolution cum Laude and a PhD in Cellular and Molecular Biology at the University of Rome “Tor Vergata”, where he also obtained a Master’s degree level in Personalized Nutrition cum Laude and qualification as a Specialist Biologist.

In the University of Rome “Tor Vergata” he continues his professional training with post-graduate grants, expanding his technical skills with an internship in Luxembourg, at the Laboratory of Cellular and Molecular Biology directed by Prof. Diederich and an internship in Germany, at the Laboratory directed by Prof. Grassingher at the University Hospital of Regensburg, to learn the techniques for setting up and maintaining stroma/cells co-cultures.

Since October 2024 he has been a fixed-term and defined-term type A researcher in the scientific disciplinary sector BIOS-10/A CELLULAR AND APPLIED BIOLOGY (ex. BIO/13) at the International University of Health and Medical Sciences UNICAMILLUS, Rome, Italy, where he also provides personalized educational tutoring services.

Since September 2022, he has obtained post-doc research contracts at the Laboratory of Experimental Immunology of the Istituto Dermopatico dell’Immacolata (IDI-IRCCS) in Rome for the study of 3D printing of human skin constructs and squamous cell tumors and for the study of the response to immunotherapy with immunological checkpoint inhibitors in skin tumors.

His research activities is focused in the preparation of some matrices, and their use, in the bioprinting of human skin constructs made up of human fibroblasts and keratinocytes. He is also involved in developing alternative techniques for incorporating squamous cell carcinoma cells into bioprinted skin constructs by obtaining spheroids from cell lines.

He study also the immune response to immunotherapy with immunological checkpoint inhibitors in skin tumors.

During the years he has been involved in the identification of anti-tumor therapies, studying both the physiological mechanisms of apoptotic induction and the effect of cytotoxic treatments (high doses of drugs) and metronomic therapy (low doses of chemotherapeutic agents) on growth and repopulation of tumor cells and the study of the anti-tumor effects of natural compounds, the anti-apoptotic effect of static and pulsating magnetic fields on biological systems and the biological effects of nanoparticles.